We evaluated the efficacy and safety of a twodrug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42–97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2–5.6%). Switch to DTG R uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy / A. Castagna, S. Rusconi, R. Gulminetti, S. Bonora, G. Mazzola, M.E. Quiros-Roldan, G.V.D. Socio, N. Ladisa, S. Carosella, A. Cattelan, S. Di Giambenedetto, M. Mena, A. Poli, L. Galli, A. Riva. - In: AIDS. - ISSN 0269-9370. - 37:1(2019 Jun 01), pp. 1256-1260.
Titolo: | Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy |
Autori: | RUSCONI, STEFANO (Secondo) |
Settore Scientifico Disciplinare: | Settore MED/17 - Malattie Infettive |
Data di pubblicazione: | 1-giu-2019 |
Rivista: | |
Tipologia: | Article (author) |
Data ahead of print / Data di stampa: | 11-mar-2019 |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1097/QAD.0000000000002188 |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
DAU_AIDS, March 2019.pdf | Post-print, accepted manuscript ecc. (versione accettata dall'editore) | Open Access Visualizza/Apri | ||
application-pdf.pdf | Publisher's version/PDF | Administrator Richiedi una copia |